Next, we aimed to investigate whether common targeted therapies for CLL, specifically those that inhibit BTK (e.g., ibrutinib) or BCL2 (e.g., venetoclax), exert effects through the induction of ferroptosis. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.